Results 51 to 60 of about 4,936 (166)
, 2012 Background: Force, Lynch and Conery proposed the duplication-degeneration-complementation (DDC) model in which partitioning of ancestral functions (subfunctionalization) and acquisition of novel functions (neofunctionalization) were the two primary ...
Lall, Santosh P. +3 more
core +1 more source
, 2017 Clofibrate is a known rodent hepatotoxicant classically associated with hepatocellular hypertrophy and increased serum activities of cellular alanine aminotransferase/aspartate aminotransferase (ALT/AST) in the absence of microscopic hepatocellular ...
Balázs Bánfai +6 more
core +1 more source
Comparison of the efficacy of Clofibrate with Phenobarbital in decreasing neonatal hyperbilirubinemia [PDF]
Background: Hyperbilirubinemia is a common problem in newborn infants. It can progress to kernicterus in severe forms, unless an intervention is initiated.
احدی, عادل +4 more
core
, 1982 Peroxisomes contain enzymes catalyzing the β-oxidation of fatty acids, which have been purified and partially characterized. Hypolipidemic drugs, including clofibrate, cause a marked proliferation of peroxisomes and a striking increase in the activity of
Fujiki, Yukio +7 more
core +1 more source
, 2010 Objective: this study was designed to determine the effect of clofibrate on neonatal uncomplicated jaundice treated with home phototherapy. Methods: This clinical trial study was performed on 60 newborns with jaundice that received home phototherapy ...
Mortazavi, Zhaleh +3 more
core
Synthesis and Biological Evaluation of New Clofibrate Analogues as Potential PPARa Agonists
, 2005 Clofibrate is a lipid-profile modifying agent belonging to the fibrate class of drugs. Fibrates are known to exhibit their beneficial effects by activating peroxisome proliferator-activated receptor-a (PPARa) and used in the treatment of dyslipidemia ...
SCIARRONI A. F +7 more
core +1 more source
Long-term trial with Colestipol plus clofibrate in familial hypercholesterolemia
, 1978 Twenty subjects with familial hypercholesterolemia (12 Type IIa and 8 Type IIb), previously treated with Colestipol for 16 months, were subjected to therapy with Colestipol (15 g/day) + clofibrate (2 g/day) for 15 months.
G. Baggio +6 more
core
, 1976 Arginine-induced insulin secretion was evaluated in 13 patients with endogenous hypertriglyceridemia (Fredrickson's Type IV) before and after a two-month period of Clofibrate therapy.
A. Tiengo +4 more
core